PharmTech News

Articles

The companies have agreements to supply its mRNA-based COVID-19 vaccine to Japan and Canada, pending regulatory approvals in those countries.

Pfizer and BioNTech to Supply Japan and Canada with mRNA-Based COVID-19 Vaccine Candidate

The companies have entered into an exclusive licensing agreement to develop, manufacture, and commercialize efinopegdutide, an investigational drug for treating nonalcoholic steatohepatitis.

Merck, Hanmi Pharmaceutical Partner in $870-Million Deal to Develop Liver Disease Drug

Sangamo will receive a $75 million upfront license fee payment and will be eligible to earn up to $720 million in other development and commercial milestone payments, including up to $420 million in development milestones and up to $300 million in commercial milestones. 

Novartis and Sangamo Announce Gene Therapy Collaboration for up to $795 Million

Pending approval of the Pfizer and BioNTech mRNA-based vaccine candidate against SARS-COV-2, the companies will supply the US government with an initial 100 million doses. 

Pfizer and BioNTech Sign Supply Agreement with US Government for Vaccine Candidate

Strong immune response by patients receiving two doses of vaccine suggests a possible treatment strategy.

AstraZeneca Vaccine Shows Antibody and T-cell responses

Udit Batra, PhD has been named Waters’ new president and CEO, effective September 1, 2020.

Waters Corporation Names New President and CEO

Through the deal, Roche will gain co-commercialization rights to pralsetinib, Blueprint Medicine’s investigational, once-daily oral precision therapy for the treatment of RET-altered non-small cell lung cancer, medullary thyroid cancer, and other types of thyroid cancer

Roche, Blueprint Medicines Enter $1.7-Billion Deal for Anti-Cancer Drug

BARDA and DOD have awarded a $450-million contract to Regeneron Pharmaceuticals to manufacture and supply an investigational double antibody cocktail in development for treating COVID-19.

BARDA, DOD Award $450-Million COVID-19 Manufacturing and Supply Contract to Regeneron

The agreement will fund the late-stage clinical development, a Phase III clinical trial, large-scale manufacturing, and the delivery of 100 million doses of Novavax’s COVID-19 vaccine candidate, NVX‑CoV2373. 

Novavax Awarded $1.6 Billion from Operation Warp Speed

Emergent is entering into a five-year agreement with Janssen Pharmaceuticals for the large-scale drug substance manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine, Ad26.COV2-S.

Top News